Tradestie Institutional Equity Comparison Engine

SRPT vs IONS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRPT Overall Edge

SRPT Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sarepta Therapeutics,, Inc. Common Stock (SRPT) driven by superior Valuation, Growth & Margin, Momentum & Technical while IONS counters with relative strength in Options & Structure. Fundamentally, SRPT trades at 10.8x Forward P/E with -0.4% operating margin (-4.5% YoY revenue) versus IONS at 90.9x Forward P/E and -58.8% operating margin (+54.9% YoY). In options structure, SRPT sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro) against IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner SRPT
SRPT 10.8x vs IONS 90.9x Fwd P/E
Growth & Margin Winner SRPT
Op Margin -0.4% vs -58.8% ยท YoY -4.5% vs +54.9%
Momentum & Technical Winner SRPT
1Y -15.0% vs -59.1% ยท 52W Pos 5% vs 2%
Options & Structure Winner IONS
BREAKDOWN (7th %ile IV) vs BREAKDOWN (17th %ile IV)
SRPT NASDAQ
Sarepta Therapeutics,, Inc. Common Stock
Pharmaceutical Preparations
$15.14
-5.76% 1D
Market Cap $1.7B
1M Return -11.44%
1Y Return -15.02%
Forward P/E 10.8x
Unified AI Score
37.8 / 100 SELL
Tech 32.0 Fund 51.0 Flow 71.0 Mom 60.0
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
1M Return -33.48%
1Y Return -59.1%
Forward P/E 90.9x
Unified AI Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SRPT -15.02% IONS -59.1% Spread: +44.08 pp (SRPT Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period SRPT Revenue IONS Revenue SRPT Op. Margin IONS Op. Margin Margin Edge
FY2018 $300M $600M -114.1% -10.2% IONS
FY2019 $380M $1.12B -185.3% 32.6% IONS
FY2020 $460M $730M -123.8% -23.6% IONS
FY2021 $610M $810M -75.1% -3.7% IONS
FY2022 $840M $590M -63.5% -69.8% SRPT
FY2023 $1.14B $790M -23.4% -44.9% SRPT
FY2024 $1.79B $710M 12.2% -67.4% SRPT
FY2025 $1.86B $940M -37.5% -40.4% SRPT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SRPT (6) vs IONS (4)
Institutional Metric SRPT IONS Criterion Row Winner
Market Capitalization Scale $1.7B $4.7B Larger Scale IONS
Trailing P/E Ratio Valuation N/M 90.9x Lower Multiple IONS
Forward P/E Ratio Valuation 10.8x 90.9x Lower Multiple SRPT
Revenue Growth (YoY) Growth -4.5% +54.9% Higher Growth IONS
Operating Margin (TTM) Profitability -0.4% -58.8% Higher Margin SRPT
Net Profit Margin Profitability -5.9% -56.9% Higher Margin SRPT
Return on Equity (ROE) Capital Efficiency -8.1% -108.0% Higher ROE SRPT
52-Week Range Position Momentum 5% ($15โ€“$25) 2% ($27โ€“$87) Stronger Trend SRPT
Beta / 30D Volatility Risk Regime 1.47ฮฒ ยท 58% Vol 0.18ฮฒ ยท 86% Vol Lower Realized Risk SRPT
Unified Institutional Score Composite Signal 37.8 / 100 (SELL) 63.9 / 100 (BUY) Higher Composite IONS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SRPT vs IONS Buy Guide
SRPT BREAKDOWN
52d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 7th %ile
IV Regime Compressed (<25th %ile)
Live SRPT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IONS BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live IONS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SRPT nor IONS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.